AbCellera Biologics Inc (ABCL)
3.89
-0.06
(-1.52%)
USD |
NASDAQ |
May 10, 13:57
AbCellera Biologics Cash from Investing (TTM): -221.11M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -221.11M |
| September 30, 2023 | -213.85M |
| June 30, 2023 | -483.06M |
| March 31, 2023 | -475.86M |
| December 31, 2022 | -352.62M |
| September 30, 2022 | -336.71M |
| June 30, 2022 | -324.34M |
| Date | Value |
|---|---|
| March 31, 2022 | -342.78M |
| December 31, 2021 | -332.25M |
| September 30, 2021 | -439.28M |
| June 30, 2021 | -173.54M |
| March 31, 2021 | -130.04M |
| December 31, 2020 | -119.78M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-483.06M
Minimum
Jun 2023
-119.78M
Maximum
Dec 2020
-303.48M
Average
-332.25M
Median
Dec 2021
Cash from Investing (TTM) Benchmarks
| Acasti Pharma Inc | -1.452M |
| Aurinia Pharmaceuticals Inc | -6.706M |
| Edesa Biotech Inc | 0.00 |
| Lexaria Bioscience Corp | -0.1991M |
| InMed Pharmaceuticals Inc | -0.1711M |